Home › Prostate Cancer › NCT06817668
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
Evaluating Tolerability of Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT) With High Dose Rate Brachytherapy Boost for Unfavorable and Higher Risk Prostate Cancer
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Capable of providing informed consent and HIPAA authorization 3. Karnofsky performance score ≥ 70 4. Pathologically confirmed unfavorable intermediate, high, and very high-risk prostate cancer per treating physician 5. Candidate plans to undergo the standard of care prostate high dose brachytherapy boost procedure Exclusion Criteria: 1. Prior pelvic irradiation treatment 2. Prior rectal surgery which precludes instrumentation with rectal ultrasound probe. 3. Evidence of nodal or distant disease on screening diagnostic work up. 4. Prior prostatectomy, Holmium laser enucleation of the prostate or transurethral resection of the prostate procedure 5. International Prostate Symptom Score (IPSS) score \> 16 despite medical therapy
About the study
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).
What is being tested
- ePURT 5Gy x 5 fractions with single HDR boost of 15Gy (radiation)
Sponsor: Indiana University · Participants: 31 · Started: Mar 5, 2025
Contact the study team
- Omar Ishaq, MD · Phone: 317-944-2524
- Kathy Lauer, BA · Phone: 317-962-3172
Official record on ClinicalTrials.gov — NCT06817668
Locations in the U.S.
| Indiana | Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.